Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ataru Inagaki

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica|January 9, 2019
[Safety of Long-acting Injectable Antipsychotics Is Long-acting Injection a High-risk Treatment Option?]Ataru Inagaki
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica|April 10, 2014
[Metabolic and lithium monitoring in Japanese psychiatric outpatient clinics]Ataru Inagaki, Tadashi Takeshima
Psychiatry and Clinical Neurosciences|January 21, 2015
Psychotropic dose equivalence in JapanToshiya Inada, Ataru Inagaki
Neuropsychiatric Disease and Treatment|November 3, 2025
Increased Antidepressant Prescriptions for Children and Adolescents with Major Depressive Disorder in Japan Based on a Claims DatabaseKeisuke Nomoto, Ataru Inagaki, Keita Yamauchi
Human Psychopharmacology|August 19, 2003
Efficacy of diazepam as an anti-anxiety agent: meta-analysis of double-blind, randomized controlled trials carried out in JapanToshiya Inada, Shoko Nozaki, Ataru Inagaki, et al.
The Keio Journal of Medicine|December 28, 2006
Time course of cerebral blood flow changes following electroconvulsive therapy in depressive patients--measured at 3 time points using single photon emission computed tomographyHarumasa Takano, Motoichiro Kato, Ataru Inagaki, et al.
Neuropsychiatric Disease and Treatment|September 5, 2014
Influence of patient characteristics on care time in patients hospitalized with schizophreniaYukiko Sugibayashi, Kimio Yoshimura, Keita Yamauchi, et al.
Journal of Medical Economics|April 10, 2020
Budget impact analysis of long acting injection for schizophrenia in JapanMami Kasahara-Kiritani, Amish Chaturvedi, Ataru Inagaki, et al.
Human Psychopharmacology|June 17, 2011
The inter-rater reliability of the Japanese version of the Inventory of Depressive Symptomatology, clinician versionNobutomo Yamamoto, Sachiko Kawakami, Koichi Sato, et al.
Advances in Therapy|June 6, 2020
Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in JapanNakao Iwata, Ataru Inagaki, Hiromi Sano, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica|January 9, 2019
[Safety of Long-acting Injectable Antipsychotics Is Long-acting Injection a High-risk Treatment Option?]Ataru Inagaki
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica|April 10, 2014
[Metabolic and lithium monitoring in Japanese psychiatric outpatient clinics]Ataru Inagaki, Tadashi Takeshima
Psychiatry and Clinical Neurosciences|January 21, 2015
Psychotropic dose equivalence in JapanToshiya Inada, Ataru Inagaki
Neuropsychiatric Disease and Treatment|November 3, 2025
Increased Antidepressant Prescriptions for Children and Adolescents with Major Depressive Disorder in Japan Based on a Claims DatabaseKeisuke Nomoto, Ataru Inagaki, Keita Yamauchi
Human Psychopharmacology|August 19, 2003
Efficacy of diazepam as an anti-anxiety agent: meta-analysis of double-blind, randomized controlled trials carried out in JapanToshiya Inada, Shoko Nozaki, Ataru Inagaki, et al.
The Keio Journal of Medicine|December 28, 2006
Time course of cerebral blood flow changes following electroconvulsive therapy in depressive patients--measured at 3 time points using single photon emission computed tomographyHarumasa Takano, Motoichiro Kato, Ataru Inagaki, et al.
Neuropsychiatric Disease and Treatment|September 5, 2014
Influence of patient characteristics on care time in patients hospitalized with schizophreniaYukiko Sugibayashi, Kimio Yoshimura, Keita Yamauchi, et al.
Journal of Medical Economics|April 10, 2020
Budget impact analysis of long acting injection for schizophrenia in JapanMami Kasahara-Kiritani, Amish Chaturvedi, Ataru Inagaki, et al.
Human Psychopharmacology|June 17, 2011
The inter-rater reliability of the Japanese version of the Inventory of Depressive Symptomatology, clinician versionNobutomo Yamamoto, Sachiko Kawakami, Koichi Sato, et al.
Advances in Therapy|June 6, 2020
Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in JapanNakao Iwata, Ataru Inagaki, Hiromi Sano, et al.
Pageof 3